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St. John's Wort for Depression 
Clinical Question 
Does St. John's wort relieve depression in adult patients? 
Evidence-Based Answer 
St. John's wort is safe and effective for short-term (six to eight weeks) relief of mild to moderate 
depression in adults. [Strength of recommendation: A, based on consistent evidence from high-
quality systematic reviews] 
Evidence Summary 
Although not widely accepted by physicians in the United States, the extract of the herb 
Hypericum perforatum, known as St. John's wort, is the most commonly prescribed treatment for 
depression in Germany.1 Preparations generally are standardized to the hypericum component, 
with dosages ranging from 500 to 1,800 mg daily. Its mechanism of action is thought to be 
inhibition of reuptake of serotonin, dopamine, and norepinephrine.2 
A Cochrane review1 of 14 randomized controlled trials (RCTs) with a total of 960 patients 
compared single preparations of St. John's wort with placebo. Patients in the included studies 
were recruited from practices of psychiatrists, general practitioners, internists, and one 
gynecologist; most of the patients were diagnosed with mild to moderate depression. All trials 
lasted four to six weeks and used various dosages of St. John's wort. Treatment response was 
assessed with one of two widely used instruments, the Hamilton Depression Scale or the Clinical 
Global Impression Index. A "responder” was defined as a patient with a clinically significant 
change in these scales. 
The pooled response rate ratio (RR, the ratio of treatment group responders to control group 
responders) was 2.5 (95 percent confidence interval [CI], 1.7 to 3.6), indicating a significant 
benefit. The pooled response rate was 56 percent in the treatment group and 25 percent in the 
control group. The number needed to treat for the combined population was 3.2. 
Five studies of 691 patients compared St. John's wort with standard antidepressants (mostly 
tricyclic antidepressants at relatively low dosages) and found them to be equally effective in 
relieving symptoms of depression (RR: 1.01; 95 percent CI, 0.87 to 1.16). St. John's wort was 
better tolerated with 26.3 percent of users reporting side effects compared with 44.7 percent in 
those taking antidepressants. There also were fewer dropouts from side effects (RR: 0.4; 95 
percent CI, 0.2 to 0.8). 
Effectiveness of St. John's Wort 
 
Review Number of studies (patients) Treatment duration Responder rate ratio* (95% CI) 
Linde, Mulrow 
(Cochrane) 
14 (960) 4 to 6 weeks 2.5 (1.7 to 3.6) 
Whiskey, et al. 14 (1,319) 4 to 8 weeks 2.0 (1.5 to 2.6) 
 
CI = confidence interval. 
*-Responder rate ratio is the ratio of treatment group responders to placebo group responders. 
Information from references 1 and 3. 
A second, more recent meta-analysis,3 which included many of the studies of the first meta-
analysis and a few others, pooled data from 14 RCTs using 1,319 patients. It had results similar 
to the first meta-analysis and confirmed that St. John's wort is superior to placebo (RR: 2.0; 95 
percent CI, 1.5 to 2.6). When compared with antidepressants in nine studies (1,457 patients), St. 
John's wort was equally effective (RR: 1.0; 95 percent CI, 0.9 to 1.1). Tricyclic antidepressants 
were used in eight studies and fluoxetine in a single study of 149 patients. Three studies with 155 
patients reported adverse drug reactions and found no significant difference when compared with 
placebo (RR: 1.0; 95 percent CI, 0.7 to 1.6). Five studies of 324 patients reported St. John's wort 
had significantly fewer side effects than tricyclic antidepressants (RR: 0.59; 95 percent CI, 0.52 
to 0.71), although data are lacking for a comparison with newer antidepressants. These results 
are supported by a smaller systematic review and meta-analysis.4,5 
It is important to note that St. John's wort is not effective for treating severe major depression, 
according to one study.6 
Side effects of St. John's wort therapy mostly are self-limited and include headache, fatigue, 
gastrointestinal upset, and restlessness. Photosensitivity is possible, but only with very high 
dosages.7 Interactions with other drugs are not well defined, but cases of induction of hepatic 
cytochrome P450 have been reported.8 Serotonin syndrome has occurred when St. John's wort is 
used with selective serotonin reuptake inhibitors (SSRIs), particularly in older patients.8 
Serotonin syndrome is caused by a systemic excess of serotonin and is defined when at least 
three of the following signs and symptoms are present: mental status changes, diaphoresis, 
myoclonus, hyperreflexia, diarrhea, fever, tremor, incoordination, seizures, tachycardia, and QT 
interval prolongation.9 
Recommendations from Others 
According to the American College of Physicians, St. John's wort is an option for short-term 
treatment of mild to moderate depression although it is not approved by the U.S. Food and Drug 
Administration.10 Preparations of St. John's wort vary in content of active ingredients. 
The Institute for Clinical Systems Improvement states that St. John's wort is more effective than 
placebo and as effective as low-dose tricyclic antidepressants for mild to moderate depression. 
St. John's wort may be as effective as SSRIs for mild to moderate depression (studies are 
lacking), and it is not recommended for patients with major depression.11 
Clinical Commentary 
SSRIs are the most widely used antidepressants in the United States. Barriers to their use include 
cost, side effects, and the reluctance of some patients to use "drugs” to treat depression. The 
evidence clearly shows that St. John's wort is an effective and well-tolerated option for short-
term relief of mild to moderate depression. It is inexpensive and may be more acceptable to 
patients who prefer "natural” therapy. 
Ideal dosages of St. John's wort are not clearly defined. A typical dosage is 300 mg of a 
standardized preparation three times daily (average cost is $10 for one month). 
It is not well established how St. John's wort compares with other antidepressants, particularly 
SSRIs. More studies comparing standard dosages of St. John's wort with SSRIs and other 
antidepressants for long-term treatment are warranted, as are systematic studies of its long-term 
side effects and interactions with other drugs. 
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